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ABSTRACT
Introduction: Vasopressin is an alternative
vasopressor in the management of septic shock. It
spares catecholamine use but whether it improves
outcome remains uncertain. Current evidence suggests
that it may be most effective if used early and possibly
in conjunction with corticosteroids. This trial will
compare vasopressin to noradrenaline as initial
vasopressor in the management of adult septic shock
and investigate whether there is an interaction of
vasopressin with corticosteroids.
Methods and analysis: This is a multicentre,
factorial (2×2), randomised, double-blind, placebo-
controlled trial. 412 patients will be recruited from
multiple UK intensive care units and randomised to
receive vasopressin (0–0.06 U/min) or noradrenaline
(0–12 µg/min) as a continuous intravenous infusion as
initial vasopressor therapy. If maximum infusion rates
of this first study drug are reached, the patient will be
treated with either hydrocortisone (initially 50 mg
intravenous bolus six-hourly) or placebo, before
additional open-label catecholamine vasopressors are
prescribed. The primary outcome of the trial will be the
difference in renal failure-free days between treatment
groups. Secondary outcomes include need for renal
replacement therapy, survival rates, other organ failures
and resource utilisation.
Ethics and dissemination: The trial protocol and
information sheets have received a favourable opinion
from the Oxford A Research Ethics Committee (12/SC/
0014). There is an independent Data Monitoring and
Ethics Committee and independent membership of the
Trial Steering Committee including patient and public
involvement. The trial results will be published in peer-
reviewed journals and presented at national and
international scientific meetings.
Trial registration number: ISRCTN 20769191 and
EudraCT 2011-005363-24.
INTRODUCTION
Severe sepsis is an increasingly common
problem worldwide and is an important
cause of mortality (10th most common cause
of death in the USA1). In the UK, the
incidence of severe sepsis has increased 68%
over a 9-year period, such that in 2004 there
were 31 000 patients who had severe sepsis
admitted to intensive care units (ICUs) in
England, Wales and Northern Ireland.2 A
substantial number of patients will also
develop severe sepsis after admission to
intensive care,3 so the total number of severe
sepsis cases may be in excess of 45 000/
annum. As the population ages and receives
more complex medical treatments, this will
continue to rise.
Mortality from sepsis is 30–50%, propor-
tional to illness severity and the number of
organs failing. Septic shock, the most severe
form of sepsis, is deﬁned as hypotension in
response to overwhelming infection.4 As well
as appropriate antibiotic treatment, one of
the main treatments is cardiovascular resusci-
tation using intravenous ﬂuids and catechola-
mines. Although usually effective in restoring
blood pressure, catecholamines have import-
ant adverse effects and may even increase
mortality.5
Vasopressin, an endogenous stress
hormone, has been proposed as an adjunct to
catecholamines in the treatment of septic
shock. The rationale for its use is that a rela-
tive vasopressin deﬁciency occurs in septic
shock and exogenously administered vaso-
pressin restores vascular tone,6 increases
blood pressure and thus leads to a reduced
requirement for catecholamine vasopressors.7
Strengths and limitations of this study
▪ Multicentre double-blind randomised trial.
▪ Comparing vasopressin and noradrenaline as
early therapy in adult septic shock to prevent
and reduce renal dysfunction.
▪ There is no long-term follow-up.
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Furthermore, vasopressin exerts its effects via interaction
with a family of vasopressin receptors. V1a receptors are
located on vascular smooth muscle cells and are respon-
sible for vasoconstriction. Heterogeneity of the distribu-
tion of V1a receptor could have important clinical and
therapeutic implications. For example, vasopressin causes
renal efferent, but not renal afferent, artery vasoconstric-
tion thereby increasing renal perfusion pressure and
glomerular ﬁltration rate.8 In contrast, noradrenaline
interacts with α-1 receptors on renal afferent and efferent
arterioles and so noradrenaline at high doses may
decrease renal perfusion and glomerular ﬁltration rate.9
Thus, in contrast to noradrenaline, there is a compelling
organ-speciﬁc heterogeneity in the vascular responsive-
ness to vasopressin. Importantly, vasopressin also binds to
oxytocin receptors, which, in addition to their uterine
contractile effects, mediate calcium-dependent vasodila-
tion via stimulation of the nitric oxide pathway in endo-
thelial cells10 of pulmonary,11 coronary12 and cerebral
arteries.13 14
There have been two recent meta-analyses of vasopres-
sin (and its synthetic analogue terlipressin) in septic
shock published that clearly demonstrated the catechol-
amine sparing effect of vasopressin and also suggested
that its use appears safe.15 16 The effect on short-term
mortality was not so clear. Serpa Neto et al,15 using a
ﬁxed-effect model, reported a relative risk (RR) of death
in adult patients treated with vasopressin/terlipressin of
0.87 (95% CI 0.77 to 0.99). Polito et al,16 using a
random-effect model, reported an RR for vasopressin/
terlipressin of 0.91 (95% CI 0.79 to 1.05). The uncer-
tainty about the effect of vasopressin on survival rates in
septic shock is reﬂected in the 2008 international
Surviving Sepsis guidelines17 that stated “Vasopressin…
may be added to noradrenaline subsequently with antici-
pation of an effect equivalent to that of noradrenaline
alone.”
Therefore, there appears to be equipoise about the
effect of vasopressin on outcome in septic shock and
more trials are warranted. In order to design future
trials, it is important to consider the results of the
Vasopressin and Septic Shock Trial (VASST), the largest
randomised controlled trial of vasopressin until now.18 In
this multicentre trial, 779 patients who had established
septic shock were randomised to receive a blinded infu-
sion of either vasopressin or noradrenaline in addition
to conventional catecholamine vasopressors. There was
no evidence of a difference in 28-day mortality between
the treatment groups (35.4% vasopressin group and
39.3% noradrenaline group, p=0.26) or in 90-day mortal-
ity (43.9% and 49.6%, respectively, p=0.11). Importantly,
vasopressin infusion in septic shock appeared safe. The
overall serious adverse event (SAE) rate was the same in
the vasopressin and noradrenaline groups (10.3% and
10.5%, respectively), and there was no difference in spe-
ciﬁc adverse events (AEs) including myocardial ischae-
mia19 or cardiac output.20 However, in the predeﬁned
stratum of less severe shock, there was a reduced
mortality in the vasopressin group compared with the
noradrenaline group (26.5% vs 35.7% 28-day mortality,
respectively, p=0.05). There was no difference in mortal-
ity between treatment groups in patients who had more
severe shock. In a post hoc subgroup analysis, the patient
group treated with vasopressin within 12 h (n=427) had
a reduced mortality (33.2% vs 40.5%, p=0.12), but no
difference in mortality if treated with vasopressin after
12 h. In additional post hoc analyses, vasopressin treat-
ment led to lower rates of progression to renal failure
(21.2% vs 41.2%, p=0.02) and mortality (30.8% vs
54.7%, p=0.01) in patients at ‘Risk’ of renal failure, but
no difference in outcomes if renal failure was already
established.21 The Editorial accompanying the VASST
report suggested that early use of vasopressin may be
needed to produce a signiﬁcant improvement in
survival.22
Another interesting subgroup analysis from VASST23 pro-
vided strong evidence of an interaction between vasopres-
sin/noradrenaline treatment and corticosteroid treatment
(interaction p=0.008). The combination of vasopressin and
steroids led to a lower mortality compared with noradren-
aline plus steroids (35.9% vs 44.7%, respectively, p=0.03)
and less organ dysfunction demonstrated by more days
alive and free from shock, ventilation and renal failure. In
contrast, patients who were treated with vasopressin and
had no corticosteroids had an increased mortality com-
pared with patients who were treated with noradrenaline
and no steroids (33.7% vs 21.3%, respectively, p=0.06). The
use of corticosteroids in septic shock remains controversial
despite more than 40 years of research. There is good evi-
dence that they spare catecholamine requirements24 and
recent meta-analyses reported a beneﬁcial effect of pro-
longed low-dose corticosteroids in the more severely ill
patients.25 26
Therefore, in designing a further vasopressin trial in
septic shock, we decided it was essential to start vasopres-
sin administration early after the onset of hypotension
and that we should control for a potential interaction of
vasopressin with corticosteroids. Before starting this
main trial, we conducted a pilot study, Vasopressin and
Corticosteroids in Septic Shock (VACS).27 This rando-
mised controlled trial demonstrated that it was possible
to use vasopressin (up to 0.06 U/min) safely as an early
vasopressor and that there was evidence of a clinical
interaction between vasopressin and corticosteroids.
Patients randomised to vasopressin and corticosteroids
required three fewer days of vasopressin treatment and
also received less than half the total vasopressin dose
compared with patients randomised to vasopressin and
placebo.27
This protocol describes the main trial that compares
vasopressin to noradrenaline as initial vasopressor in the
management of adult septic shock. As there may be an
interaction of vasopressin with corticosteroids, the use of
corticosteroids will also be controlled but only given to
patients who are poorly responsive to ﬂuids and vaso-
pressors, according to international guidelines.17
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METHODS AND ANALYSIS
The VAsopressin versus Noradrenaline as Initial therapy
in Septic sHock (VANISH) trial is a multicentre pro-
spective, factorial (2×2), randomised, double-blind,
placebo-controlled trial. The trial is sponsored by
Imperial College London and coordinated by the
Imperial Clinical Trials Unit. The trial will be conducted
in accordance with the principles of the Declaration of
Helsinki and Good Clinical Practice. It is registered on
the European Union Drug Regulating Authorities
Clinical Trials database (EudraCT 2011-005363-24) and
the International Standardised Randomised Controlled
Trial Registry (ISRCTN20769191). The study is jointly
funded by the National Institute for Health Research
(NIHR) under its Research for Patient Beneﬁt
Programme and the NIHR Clinician Scientist fellowship
award scheme.
The primary objectives of this trial are:
1. To test whether vasopressin reduces renal dysfunction
compared with noradrenaline when used as the
initial vasopressor in the management of adult
patients who have septic shock.
2. To test whether there is an interaction between vaso-
pressin and corticosteroids when used in the manage-
ment of septic shock.
The secondary objectives are to assess whether vaso-
pressin improves other secondary outcomes (need for
dialysis, survival rates, other organ failures and resource
usage) compared with noradrenaline in the manage-
ment of septic shock in adult patients.
Setting
The trial will be conducted in multiple general adult
ICUs within the UK and will recruit 412 patients.
Patients will be randomised to receive vasopressin (0–
0.06 U/min) or noradrenaline (0–12 µg/min) as the
initial vasopressor therapy to maintain mean arterial
blood pressure after adequate ﬂuid resuscitation. This
ﬁrst study drug will continue as a continuous intravenous
infusion until the septic shock has resolved and the
patient no longer requires vasopressor support.
If maximum doses of the ﬁrst study drug are reached
(4.5 mL/h of the blinded infusion), the patient will be
treated with the second study drug (hydrocortisone or
placebo), before additional clinically indicated vasopres-
sors/inotropes are prescribed (see ﬁgure 1).
Subject selection
Inclusion criteria
The target population is adult patients who require vaso-
pressors for the management of sepsis despite ﬂuid
resuscitation.
Inclusion criteria will use the internationally estab-
lished consensus deﬁnitions of sepsis.4 In brief:
▸ Fulﬁl 2/4 of the criteria of the systemic inﬂammatory
response syndrome (SIRS) due to known or sus-
pected infection within the previous 24 h. The SIRS
criteria are:
1. Fever (>38°C) or hypothermia (<36°C),
2. Tachycardia (heart rate >90 bpm),
3. Tachypnoea (respiratory rate >20 breaths/min or
paCO2 <4.3 kPa) or need for mechanical ventilation,
4. Abnormal leucocyte count (>12 000cells/mm3, <4000
cells/mm3 or >10% immature (band) forms).
▸ Hypotension despite adequate intravenous ﬂuid
resuscitation (suggested minimum of 1 L in the previ-
ous 4 h, some patients may need considerably more).
Exclusion criteria
▸ Patient has received a continuous infusion of vaso-
pressors previously during this ICU admission (other
than vasopressors used as emergency treatment (for
less than 6 h) to stabilise the patient during this
episode). Vasopressors include noradrenaline, epi-
nephrine, vasopressin, dopamine, metaraminol,
phenylephrine and (intermittent) terlipressin.
▸ Regular systemic corticosteroid therapy within the
previous 3 months (this does not include inhaled
steroid therapy).
▸ Known adrenal dysfunction/insufﬁciency.
▸ End-stage renal failure (ie, requiring long-term
dialysis).
▸ Physician and team are not committed to full active
care.
▸ Patient is known to be pregnant.
▸ Patient has known acute mesenteric ischaemia.
▸ Patient is known to have Raynaud’s phenomenon, sys-
temic sclerosis or other vasospastic diseases.
▸ Patient has been enrolled in another clinical trial of
an investigational medicinal product within 30 days or
is enrolled in another interventional study that might
interact with the study drugs.
▸ Patient has a history of anaphylaxis or hypersensitivity
to any study drug.
Screening
All patients who are clinically judged to have septic
shock will be screened against the inclusion and exclu-
sion criteria to be eligible for the study.
Randomisation
Randomisation (with concealed allocation) will be by
pre-prepared computer-generated randomised number
and will use the InForm (Oracle Corp, California, USA)
online system. Randomisation will be stratiﬁed by ICU
and will occur on a 1:1 basis in permuted blocks.
Interventions
The four treatment arms will be:
1. Vasopressin+hydrocortisone;
2. Vasopressin+placebo;
3. Noradrenaline+hydrocortisone;
4. Noradrenaline+placebo.
Study drug 1 will be vasopressin (0–0.06 U/min) or
noradrenaline (0–12 µg/min) and this will be used as the
ﬁrst-line vasopressor for the management of septic shock.
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After study inclusion and randomisation, study drug 1
will be given via continuous infusion through a central
intravenous line and titrated by the bedside nurse to
achieve and maintain a target mean arterial pressure
(65–75 mm Hg). The treating physician may alter the
target mean arterial pressure if clinically indicated.
All study drugs will be supplied to the ICU as speciﬁc
research study drugs and they will be stored in separate
research stores (eg, locked boxes in ICU). All drugs will
be drawn up by the bedside critical care nurse. Blinding
of all clinical staff, patients and researchers will be main-
tained through the use of overlabelling on the body and
neck of normal drug ampoules, and matching placebo
ampoules will be manufactured by Sharp Clinical
Services (Powys, Wales).
Study drug 1 will come as three ampoules: one small
ampoule (2 mL) and two large ampoules (4 mL); one
size of ampoule will contain active drug (vasopressin or
noradrenaline) and one will contain saline. All three
ampoules (total 10 mL) will be added to 40 mL of 5%
dextrose into a syringe. The infusion will be started at
1 mL/h (equal to vasopressin 0.013 U/min or noradren-
aline 2.66 µg/min) and increased to a maximum of
4.5 mL/h (equal to vasopressin 0.06 U/min or nor-
adrenaline 12 µg/min), as clinically indicated to
achieve/maintain the target mean arterial pressure.
If the maximum limit of study drug 1 is reached
(4.5 mL/h), then study drug 2 will be administered.
This will be either hydrocortisone phosphate (50 mg) or
placebo (0.9% saline), and 0.5 mL of study drug 2 will
be administered by intravenous injection six-hourly. This
study drug will be administered for 5 days and then
tapered to 0.5 mL every 12 h for days 6–8, 0.5 mL every
24 h for days 9–11, and then stopped. If the septic shock
has reversed (ie, all vasopressin and catecholamine infu-
sion stopped) before these timescales, then the phys-
ician may taper study drug 2 more quickly.
If additional vasopressors are required to maintain
blood pressure after the maximum rate of study drug 1
is reached (4.5 mL/h) and the ﬁrst dose of study drug 2
Figure 1 Patient flow. BP, blood pressure; IV, intravenous.
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(hydrocortisone or 0.9% saline) has been administered,
then the treating physician may start any catecholamine
vasopressor as clinically indicated (no additional vaso-
pressin or vasopressin analogue is allowed).
The study drugs should not be started until the treat-
ing physician is conﬁdent that adequate ﬂuid resuscita-
tion has been achieved. Adequate ﬂuid resuscitation
should be achieved using repeated ﬂuid challenges.
Examples of appropriate targets include any or all of the
following:
▸ Central venous pressure ≥8 mm Hg (≥12 mm Hg in
mechanically ventilated patients);
▸ Urine output >0.5 mL/kg/h;
▸ ScvO2 ≥70%;
▸ Good peripheral perfusion on clinical examination;
▸ Other measures of cardiac output/ﬂow.
During the study drug administration and especially
during the ﬁrst 6 h, patients must be repeatedly reas-
sessed to ensure adequate ﬂuid resuscitation using any
or all of the targets above.
Study drug 1 infusion will continue until the septic
shock has resolved. When a patient is recovering from
septic shock, any open-label catecholamine vasopressor
infusions will be weaned ﬁrst, followed by study drug
1. The rate of weaning of the drugs should be as clinic-
ally indicated to maintain the target mean arterial pres-
sure. Once study drug 1 has stopped if vasopressors are
required within 24 h, study drug 1 should be restarted.
If more than 24 h have elapsed and vasopressors are
required again these could be with any open-label vaso-
pressors at the treating physician’s discretion. Other
management of septic shock, including use of inotropes
(eg, dobutamine), will be at the treating physician’s dis-
cretion, based on the international ‘Surviving Sepsis’
guidelines.17 High-volume haemoﬁltration for the man-
agement of sepsis (ie, renal replacement therapy not to
treat kidney failure) should not be used.
Emergency treatment
Study drug 1 should be given as the initial vasopressor
to treat septic shock. However, in an emergency situ-
ation, the patient’s blood pressure should be stabilised
using any clinically indicated vasopressors and/or ino-
tropes. As soon as the clinical situation has stabilised,
these other vasopressors should be replaced by study
drug 1 according to the study protocol and no later
than 6 h. Use of emergency vasopressors in this situation
will not be an exclusion criteria or protocol violation.
Rescue steroid therapy
If patients are receiving study drugs 1 and 2 and are not
responding to open-label catecholamine vasopressors
(ie, life-threatening hypotension), then they may be
administered intravenous hydrocortisone therapy as
rescue therapy. This should not occur until the treating
physician has reassessed ﬂuid resuscitation status and a
reasonable dose of catecholamine has been given an
opportunity to increase the blood pressure (suggested
≥0.5 µg/kg/min of noradrenaline or equivalent). In this
situation, study drug 2 should be stopped and open-label
steroid given as per the treating physician’s prescription.
Study drug 1 should continue.
Similarly, if after inclusion, systemic steroids are
required to treat another medical condition (ie, not
septic shock) then study drug 2 should be stopped and
the necessary steroid prescribed. Study drug 1 should
continue. Inhaled steroids can be prescribed as clinically
indicated at any time. All other drugs (other than vaso-
pressors) should be prescribed as clinically indicated.
Unblinding
It is unlikely that there would be a need to unblind the
study drugs. The vasopressor infusions have very short
half-lives, and therefore if there was an AE, the drug
could be stopped and any effects would wear off in
minutes. However, emergency envelopes will be supplied
to each hospital pharmacy to allow emergency unblind-
ing if needed.
The local investigators should aim to discuss the need
for unblinding with the trial coordinator or chief investi-
gator beforehand.
Laboratory evaluations
Blood and urine sampling will be carried out in select
centres. Blood, 25 mL for plasma, serum, RNA and DNA
samples and urine (10 mL) will be collected on the day
of inclusion and days 3, 5 and 7 (see table 1). The
plasma samples will be collected in EDTA and spun
within 15 min; serum samples will be collected in plain
tubes and allowed to clot for 30 min before separation
and RNA samples will be collected in PAXgene blood
RNA tubes (PreAnalytiX GmbH, Switzerland). All
samples will be frozen at −80°C within 1 h and sent in
batches to the coordinating centre for storage and later
analysis. Samples will be kept beyond the end of the trial
and stored in accordance with the Human Tissue Act.
Data collection and management
Participants will be followed up daily while in the ICU
and to ascertain survival status at 28 days postrecruit-
ment and hospital discharge. Routinely collected clinical
data (cardiovascular, respiratory and renal physiological
variables as well as haematological, biochemical and
microbiological blood test results) will be recorded on a
daily basis during this time and entered directly by local
staff onto a trial speciﬁc electronic case report form
(eCRF), InForm. All personal identiﬁable data, includ-
ing screened patients, will be kept securely in the local
site ﬁles and will not be uploaded to the main trial
database.
The eCRF database generates automatic alerts for
missing, invalid or data which does not conform to the
rules established for that data type. There is an elec-
tronic audit trial for all data changes. In addition, the
central coordinating site will visit local recruiting sites to
ensure compliance with the protocol, Good Clinical
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Practice and local regulatory compliance as well as
source data veriﬁcation.
Primary outcome
The primary outcome of the trial will be the difference
in renal failure-free days (the number of days alive and
free of renal failure) during the 28 days after randomisa-
tion between treatment groups. Renal failure will be
deﬁned by the Acute Kidney Injury Network (AKIN)
group stage 3 deﬁnition28:
▸ Increase in serum creatinine to >300% (>threefold)
from baseline;
▸ Or serum creatinine ≥354 μmol/L with an acute rise
of at least 44 μmol/L;
▸ Or initiation of renal replacement therapy;
▸ Or a urine output of <0.3 mL/kg/h ≥24 h;
▸ Or anuria ≥12 h.
Secondary outcomes
Secondary outcomes will include:
▸ Rates and duration of renal replacement therapy;
▸ Length of renal failure in survivors and non-survivors;
▸ 28-day, ICU and hospital mortality rates;
▸ Organ failure-free days in the ﬁrst 28 days, assessed
using the Serial Organ Failure Assessment (SOFA)
score;29
▸ Organ support data assessed using the standard
National Health Service Healthcare Resource Groups;
▸ Blood and urinary biomarkers of renal function and
inﬂammation (for subsequent analyses).
ETHICS
The trial protocol and participant information sheets
have been reviewed by the Oxford A independent
research ethics committee and given a favourable
opinion (12/SC/0014). It has clinical trials approval
from the Medicines and Healthcare Products Regulatory
Authority (MHRA). Any substantial protocol amend-
ments will be sent to the ethics committee and MHRA
for approval as per the standard regulatory require-
ments. All sites will then be informed of the
amendments.
Informed consent
In most cases, it will not be possible to obtain prospect-
ive consent from the patient at the time of enrolment.
This is due to the fact that many patients will have a
reduced level of consciousness due to their illness or
due to sedative medication used as part of their treat-
ment. As all the study drugs are already routinely used
in the management of septic shock, there is minimal
extra risk from participation in this study. As septic
shock is a medical emergency and the fact that delays in
administering the study drugs may affect patient
outcome, the patient will be treated and samples col-
lected in the emergency situation without prospective
consent. No analysis of data or samples will occur until
retrospective consent is obtained. At the ﬁrst available
opportunity, once the clinical condition has stabilised,
retrospective consent should be sought. This process was
used in the pilot/feasibility study27 and was found to be
acceptable to clinicians, patients and their families.
Patient consent
If possible, informed consent will be obtained from the
patient. The patient will be informed about the trial by
the responsible clinician or a member of the research
team and given a copy of the patient information sheet
(PIS). Informed patients will be given an adequate
amount of time to consider their participation in the
trial. If the patient decides to participate in the trial, they
will be asked to sign the patient consent form which will
then be countersigned by the responsible clinician.
Table 1 Visit schedule
Visit
Day
1
Day
2
Day
3
Day
4
Day
5
Day
6
Day
7
Day
8–28
Screening X
Informed consent (patient consent/PerLR/ProLR/retrospective
patient information)
Retrospective consent (PerLR/ProLR) will be obtained at the
first available opportunity. Retrospective patient consent will
be obtained when the patient has recovered
Inclusion/exclusion criteria X
Randomisation X
Study drug administration (study drug 1 and 2) Study drug 1 (vasopressin/noradrenaline) continued until
shock resolved. If BP was still low, study drug 2
(hydrocortisone/placebo) administered as described in this
protocol
Follow-up
Blood and urine sampling X X X X
Daily collection of clinical data X X X X X X X X
Final visit On the day of discharge from the hospital
BP, blood pressure; PerLR, personal legal representative; ProLR, professional legal representative.
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Personal legal representative consent
If the patient is unable to give consent, informed
consent will be sought from the patient’s ‘Personal
Legal Representative’ (PerLR) who may be a relative,
partner or close friend. The PerLR will be informed
about the trial by the responsible clinician or a member
of the research team and provided with a copy of the
covering statement for PerLR with an attached PerLR
information sheet and asked to give an opinion as to
whether the patient would object to taking part in such
medical research. If the PerLR decides that the patient
would have no objection to participating in the trial,
they will be asked to sign the PerLR consent form which
will then be countersigned by the responsible clinician.
Professional legal representative consent
If the patient is unable to give informed consent and no
PerLR is immediately available, a doctor who is not con-
nected with the conduct of the trial may act as a
Professional Legal Representative (ProLR). The doctor
will be informed about the trial by the responsible clin-
ician or a member of the research team and given a
copy of the PIS. If the doctor decides that the patient is
suitable for entry into the trial, they will be asked to sign
the ProLR consent form.
Retrospective patient information
Patients for whom consent is given by a PerLR or ProLR
will be informed of their participation in the trial by the
responsible clinician or a member of the research team
once they regain capacity to understand the details of the
trial. The responsible clinician will discuss the study with
the patient and the patient will be given a copy of the PIS
to keep. The patient will be asked for consent to continue
participation in the trial and to sign the consent form. If
the patient does not want to continue participation in the
study, they will be given the choice of having already col-
lected data and samples excluded from the ﬁnal analysis.
All participants are free to withdraw at any time from the
protocol treatment without giving reasons and without
prejudicing further treatment.
If the patient dies before consent is obtained, retro-
spective consent should be sought from the PerLR (or
ProLR, if no PerLR can be identiﬁed) for inclusion and
collection of data.
Monitoring and pharmacovigilance
Given that the trial is being conducted on critically ill
patients, a signiﬁcant number of patients are likely to
experience AEs. Events that are in keeping with the
patient’s clinical condition will not be reported as AEs.
The following clinical outcomes from sepsis will not be
recorded as AEs unless the local investigator deems the
event to be related to the study drug or the protocol—
death, cardiovascular failure, respiratory failure, hepatic
failure, renal failure and haematological failure. Speciﬁc
information about the occurrence of a myocardial
infarction or acute coronary syndrome, life-threatening
arrhythmias, mesenteric ischaemia, digital ischaemia
and secondary infection will be recorded in the case
report form. All AEs will be assessed for likely relation-
ship to the study drugs. All SAEs or a suspected unex-
pected serious adverse reaction will be reported to the
trial coordination centre within 24 h and to the relevant
authorities in accordance with current regulations.
Imperial College London, the sponsor of the trial has
civil liability insurance, which covers this study in all par-
ticipating centres. Imperial College London also holds
negligent harm and non-negligent harm insurance pol-
icies which apply to this study.
Statistical analysis plan
The main analysis will be carried out on an
intention-to-treat basis. However, as not all patients will
require study drug 2, analysis will also be carried out on
an ‘as treated’ basis and sensitivity analysis performed.
Every effort will be made to minimise missing baseline
and outcome data in this trial, but prior to data analysis,
the level and pattern of the missing data will be estab-
lished and the likely causes of any missingness investi-
gated. If necessary, multiple imputation30 31 or Bayesian
methods for missing data32 will be used as appropriate
to address any issues arising.
The primary outcome, the number of days alive and
free of renal failure, is not normally distributed and has
a large spike in frequency at 28 days, the point at which
the measure is truncated. Therefore, the data will be
reported as a combination of two summary measures:
▸ The proportion of patients who survive and have no
renal failure during the 28 days after randomisation;
▸ The median number of days alive and free of renal
failure for patients who do not survive and/or experi-
ence some renal failure during the 28 days after
randomisation.
For the main analysis, we will test for a difference
between the distribution of days alive and free of renal
failure for participants randomised to vasopressin com-
pared with those randomised to noradrenaline using a
Mann-Whitney U test. A Markov model with three states
(alive and no renal failure, alive with renal failure and
death) and including indicator variables for vasopressin,
corticosteroids and vasopressin × corticosteroids (inter-
action term) will be ﬁtted to assess the possible inter-
action between vasopressin and corticosteroids, and
estimate how much of any increase in days alive and free
of renal failure can be attributed to preventing renal
failure and how much to preventing death.
The secondary outcomes will be analysed using appro-
priate regression models to compare the four treatment
groups. Comparisons of vasopressin versus noradren-
aline and corticosteroids versus placebo will also be pre-
sented, provided the strength of any interaction does
not render these ‘at the margins’ analyses unreliable.
The sample size was chosen to provide 80% power to
detect a 20–25% relative reduction of risk of developing
renal failure if treated with vasopressin compared with
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noradrenaline, assuming an overall incidence of acute
renal failure of 30–50% and a signiﬁcance level of 0.05.
The calculations were based on simulation, assuming a
Mann-Whitney U test is used to analyse the primary
outcome. The 412 patients allow for a 3% withdrawal of
consent in line with previous critical care studies within
the UK.33 Owing to the emergency nature of the trial
and the rapid timescales required for inclusion, as in
the pilot trial,27 it is possible that new clinical informa-
tion may become apparent after randomisation but
before starting the study drug. If the patient is discov-
ered to meet any exclusion criteria or not meet the
inclusion criteria before the study drug has started, they
will not be included in the trial and its analysis. These
patients will be replaced.
End of trial
The trial will end once 412 patients have been enrolled,
and the last patient has reached day 28 postenrolment
or at hospital discharge, whichever is later, or earlier if
mandated by the Trial Steering Committee (TSC) or
sponsor.
Trial monitoring and oversight
The TSC with an independent chair, independent
members including patient and public representatives
will be responsible for overseeing the progress of the
trial and will meet six-monthly. The independent Data
Monitoring and Ethics Committee (DMEC) will meet
six-monthly to review ongoing recruitment, protocol
compliance, clinical outcome and AE data. They will
provide the TSC with written reports to advise about
ongoing trial conduct.
DISSEMINATION
Results will be presented at scientiﬁc meetings and pub-
lished in peer-reviewed journals. All publications and
presentations relating to the study will be authorised by
the Trial Management Group. Authorship will be deter-
mined according to the internationally agreed criteria
for authorship. In addition, a lay summary will be avail-
able on the websites of the Imperial Clinical Trials Unit
and the Intensive Care Foundation. Investigators who
would like access to the trial data set are encouraged to
submit a brief application, outlining rationale and ana-
lytical plan, to the trial management group for approval
for additional studies.
Trials status
Recruitment is ongoing. The ﬁrst patient was recruited
in February 2013 and we expect recruitment to be com-
plete in May 2015.
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